"Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market carboplatin injection, 10mg/ml in 5ml, 15ml and 45ml," Cadila Healthcare said in a BSE filing.
New Delhi: Drug firm Zydus Cadila has received approval from the US health regulator to market carboplatin injection used for the treatment of cancer in the American market.
"Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market carboplatin injection, 10mg/ml in 5ml, 15ml and 45ml," Cadila Healthcare said in a BSE filing.
The group now has more than 100 approvals and has so far filed over 280 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-04 fiscal, it added.
Shares of Cadila Healthcare were trading at Rs 321.25 in the morning trade on BSE, up 1.36 per cent from the previous close.
Comments
0 comment